诺和大动脉动脉瘤或大动脉解剖的风险:来自全国性嵌套病例控制研究的证据与匹配的实验模型并行
Callan D Wesley1, Jarl Emanuel Strange2, Anders Holt2
1Laboratory of Physiopharmacology, Faculty of Medicine and Health Sciences and Faculty of Pharmaceutical Biomedical and Veterinary Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, Antwerp 2610, Belgium.
诺基诺 (FQ) 与大动脉动脉瘤或剖析 (AA/AD) 没有联系. 这项研究没有发现各种人群的风险增加,这表明在医学上必要时可以使用FQ.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 流行病学 流行病学
背景情况:
- 诺基诺 (FQ) 携带大动脉动脉瘤和解剖 (AA / AD) 的潜在风险,导致监管警告.
- 最近的大规模研究质疑了FQ使用与AA/AD之间确定的关联.
研究的目的:
- 调查诺基诺暴露与大动脉动脉瘤和剖析 (AA/AD) 风险之间的关联.
- 评估高风险人群和先前有大动脉疾病的患者使用FQ的安全性.
- 通过动物模型评估FQ对大动脉尺寸和动脉硬性的影响.
主要方法:
- 使用了追溯嵌套案例-队列研究设计.
- 分析包括主要和高风险人群 (老年人,高血压,有大动脉疾病的人).
- 使用西普罗夫洛克萨进行动物实验,以评估大动脉变化.
主要成果:
- 在任何人口群体中,在FQ暴露时,没有观察到AA/AD的危险比率增加.
- 在患有大动脉疾病的患者中,FQ使用与增加的死亡率或大动脉干预无关.
- 在动物模型中,西普罗夫洛克萨的使用并没有导致大动脉直径的扩大或动脉硬性的增加.
结论:
- 该研究表明,诺基诺不增加大动脉动脉瘤或剖析的风险.
- 在临床上显示时,常规使用诺基诺被认为是安全的.
- 这些发现可能有助于重新评估目前对诺基诺的处方指南.
更多相关视频
06:46Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection
Published on: July 16, 2018
09:32Manufacturing Abdominal Aorta Hydrogel Tissue-Mimicking Phantoms for Ultrasound Elastography Validation
Published on: September 19, 2018
相关概念视频
Imaging Studies for Cardiovascular System III: X-Ray
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Thiazide-Class Diuretics
Radiological Investigation I: X-ray and CT
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
